Chromogranin A: is it a useful marker of neuroendocrine tumors?
Open accessAbstract
Purpose: We evaluated the pattern of chromogranin A (CgA) plasma levels in a large number of patients with neuroendocrine tumors (NETs), in a series of patients with chronic atrophic gastritis (CAG) with and without enterochromaffin-like (ECL) cell hyperplasia, and in healthy participants (HPs). Patients and Methods: Two hundred thirty-eight patients with NETs, 42 patients with CAG with or without ECL cell hyperplasia, and 48 HPs were studied. All patients underwent a baseline visit, biochemical routine check-up, imaging techniques, endoscopy, and histologic determination. Results: CgA plasma levels were higher in patients with NETs compared with CAG patients or HPs (P < .001). In the NET group, we observed higher CgA levels in patients with diffuse disease compared with patients with local or hepatic disease (P < .001). CgA plasma levels were significantly higher in patients with Zollinger-Ellison syndrome compared with other types of endocrine tumors (P < .001). We found the best cutoff range between HPs and NET patients to be 18 to 19 U/L (sensitivity, 85.3%; specificity, 95.8%). Comparing all participants without neoplasia (HPs, CAG patients, and disease-free patients) and patients with endocrine tumors, the best cutoff range was 31 to 32 U/L (sensitivity, 75.3%; specificity, 84.2%). Setting the specificity at 95%, the cutoff range was 84 to 87 U/L (sensitivity, 55%). Conclusion: Our study confirms the high specificity and sensitivity of CgA in diagnosing an endocrine tumor. It is necessary to use a cutoff range of 84 to 87 U/L to obtain a high specificity in diagnosing NETs, with the aim of excluding patients in whom the CgA was elevated as a result of other non-neoplastic diseases.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Secretion of Chromogranin A by Peptide-Producing Endocrine Neoplasms
O’Connor, D. T., & Deftos, L. J. (1986) · New England Journal of Medicine · doi:10.1056/nejm198605013141803 · Cited by 474 · see citing works
Nobels, F. R. E., Kwekkeboom, D. J., Coopmans, W., Schoenmakers, C. H. H., Lindemans, J. W., de Herder, W. W., Krenning, E. P., Bouillon, R., & Lamberts, S. W. J. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.8.4145 · Cited by 355 · see citing works
Stridsberg, M., Öberg, K., Li, Q., Engström, U., & Lundqvist, G. (1995) · Journal of Endocrinology · doi:10.1677/joe.0.1440049 · Cited by 278 · see citing works
Chromogranin A: Its Role in Endocrine Function and as an Endocrine and Neuroendocrine Tumor Marker*
Deftos, L. J. (1991) · Endocrine Reviews · doi:10.1210/edrv-12-2-181 · Cited by 265 · see citing works
A comparison between three commercial kits for chromogranin A measurements
Stridsberg, M., Eriksson, B. K., Öberg, K., & Janson, E. (2003) · Journal of Endocrinology · doi:10.1677/joe.0.1770337 · Cited by 200 · see citing works
Endocrine pancreatic tumors: factors correlated with survival
Tomassetti, P., Campana, D., Piscitelli, L., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi358 · Cited by 193 · see citing works
Self-citationInterest of Chromogranin A for diagnosis and follow-up of endocrine tumours
Nehar, D., Lombard‐Bohas, C., Olivieri, S., Claustrat, B., Chayvialle, J., Penes, M., Sassolas, G., & Borson‐Chazot, F. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02030.x · Cited by 177 · see citing works
Clinical significance of blood chromogranin A measurement in neuroendocrine tumours
Seregni, E. C., Ferrari, L., Bajetta, E., et al. (2001) · Annals of Oncology · doi:10.1093/annonc/12.suppl_2.s69 · Cited by 150 · see citing works
PERACCHI, M., Gebbia, C., Basilisco, G., Quatrini, M., Tarantino, C., Vescarelli, C., Massironi, S., & Conte, D. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.01862 · Cited by 121 · see citing works
Nobels, F. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.8.2622 · Cited by 119 · see citing works
Diagnostic value of plasma chromogranin A in neuroendocrine tumours
Tomassetti, P., Migliori, M., Simoni, P., Casadei, R., Iasio, R. D., Corinaldesi, R., & Gullo, L. (2001) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200101000-00010 · Cited by 118 · see citing works
Self-citationPanzuto, F., Severi, C., Cannizzaro, R., et al. (2004) · Journal of Endocrinological Investigation · doi:10.1007/bf03350903 · Cited by 114 · see citing works
Giusti, M., Sidoti, M., Augeri, C., Rabitti, C., & Minuto, F. (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.1500299 · Cited by 111 · see citing works
Borch, K., Stridsberg, M., Burman, P., et al. (1997) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529709000194 · Cited by 93 · see citing works
PERACCHI, M., Conte, D., Gebbia, C., et al. (2003) · European Journal of Endocrinology · doi:10.1530/eje.0.1480039 · Cited by 75 · see citing works
Peptide Hormones as Tumor Markers in Neuroendocrine Gastrointestinal Tumors
Eriksson, B. K., & Öberg, K. (1991) · Acta Oncologica · doi:10.3109/02841869109092404 · Cited by 68 · see citing works
Chromogranin a and Pancreastatin-Like Immunoreactivity in Serum of Gastrinoma Patients
Syversen, U., Mignon, M., Bonfils, S., Kristensen, A., & Waldum, H. L. (1993) · Acta Oncologica · doi:10.3109/02841869309083906 · Cited by 68 · see citing works
Guignat, L., Bidart, J., Nocera, M., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1677 · Cited by 49 · see citing works
Schürmann, G., Raeth, U., Wiedenmann, B. J., Buhr, H. J., & Herfarth, C. H. (1992) · World Journal of Surgery · doi:10.1007/bf02067361 · Cited by 48 · see citing works
Tumour markers in neuroendocrine tumours.
Öberg, K., Janson, E. T., & Eriksson, B. (1999) · PubMed · Cited by 47 · see citing works
Abou‐Saif, A., Gibril, F., Ojeaburu, J. V., et al. (2003) · Cancer · doi:10.1002/cncr.11473 · Cited by 46 · see citing works
Endocrine Tumors of the Ileum: Factors Correlated with Survival
Tomassetti, P., Campana, D., Piscitelli, L., et al. (2006) · Neuroendocrinology · doi:10.1159/000096053 · Cited by 42 · see citing works
Self-citationBashir, S., Gibril, F., Ojeaburu, J. V., Asgharian, B., Entsuah, L. K., Ferraro, G., Crafa, P., Bordi, C., & Jensen, R. T. (2002) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2002.01249.x · Cited by 35 · see citing works
Effects of Sandostatin on Plasma Chromogranin-A Levels in Neuroendocrine Tumors*
Moattari, A. R., Deftos, L. J., & Vinik, A. I. (1989) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-69-4-902 · Cited by 35 · see citing works
Leon, A. E., TORTA, M., Dittadi, R., Uberti, E. C. D., Ambrosio, M. R., Fave, G. D., de Braud, F., Tomassetti, P., Gion, M., & Dogliotti, L. (2005) · The International Journal of Biological Markers · doi:10.1177/172460080502000303 · Cited by 33 · see citing works
Self-citationFerrari, L., Seregni, E. C., Lucignani, G., Bajetta, E., Martinetti, A., Aliberti, G., Pallotti, F., Procopio, G., della Torre, S., Luksch, R., et al. (2004) · The International Journal of Biological Markers · doi:10.5301/jbm.2008.1664 · Cited by 32 · see citing works
Kleveland, O., Syversen, U., Slørdahl, K., et al. (2001) · Digestion · doi:10.1159/000048842 · Cited by 11 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Chromogranin A—Biological Function and Clinical Utility in Neuro Endocrine Tumor Disease
Modlin, I. M., Gustafsson, B. I., Moss, S. F., Pavel, M., Tsolakis, A. V., & Kidd, M. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-1006-3 · Cited by 387 · see citing works
Neuroendocrine tumors of the gastro-entero-pancreatic system.
Massironi, S., Sciola, V., Peracchi, M., Ciafardini, C., Spampatti, M. P., & Conte, D. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.5377 · Cited by 177 · see citing works
Marotta, V., Zatelli, M. C., Sciammarella, C., Ambrosio, M. R., Bondanelli, M., Colao, A., & Faggiano, A. (2018) · Endocrine-Related Cancer · doi:10.1530/erc-17-0269 · Cited by 161 · see citing works
Knigge, U., Capdevila, J., Bartsch, D. K., Baudin, E., Falkerby, J., Kianmanesh, R., Kos-Kudla, B., Niederle, B., Nieveen van Dijkum, E., O'Toole, D., et al. (2017) · Neuroendocrinology · doi:10.1159/000458155 · Cited by 136 · see citing works
Mosli, H. H., Dennis, A., Kocha, W., Asher, L. J., & Van Uum, S. H. M. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1548 · Cited by 59 · see citing works
Vezzosi, D., Walter, T., Laplanche, A., Raoul, J. L., Dromain, C., Ruszniewski, P., d'Herbomez, M., Guigay, J., Mitry, E., Cadiot, G., et al. (2011) · The International Journal of Biological Markers · doi:10.5301/jbm.2011.8327 · Cited by 43 · see citing works
Jilesen, A. P. J., Busch, O. R. C., van Gulik, T. M., Gouma, D. J., & Nieveen van Dijkum, E. J. M. (2014) · Digestive Surgery · doi:10.1159/000370007 · Cited by 26 · see citing works
Chromogranin As a Biochemical Marker of Neuroendocrine Tumors
Lyubimova, N. V., Churikova, T. K., & Kushlinskii, N. E. (2016) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-016-3254-0 · Cited by 20 · see citing works
- Authors
- Campana, D., Nori, F., Piscitelli, L., Morselli-Labate, A. M., Pezzilli, R., Corinaldesi, R., & Tomassetti, P.
- Affiliations
- IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola (IT)
- From the Department of Internal Medicine and Gastroenterology, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
- Venue
- Journal of Clinical Oncology
- Published
- 2007-05-20
- Volume
- 25
- Issue
- 15
- Pages
- 1967-1973
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2133780035
- Cited by
- 248
- References
- 27
- Citations by year
- 2026: 3 · 2025: 12 · 2024: 5 · 2023: 4 · 2022: 7 · 2021: 10 · 2020: 18 · 2019: 11 · 2018: 15 · 2017: 24 · 2016: 16 · 2015: 21 · 2014: 16 · 2013: 24 · 2012: 21
- FWCI
- 7.73
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal Tumor Research and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Keywords
- chromogranin A, neuroendocrine tumors, plasma biomarkers, diagnostic thresholds, sensitivity and specificity, chronic atrophic gastritis, enterochromaffin-like cell hyperplasia, Zollinger-Ellison syndrome, endocrine tumors
- MeSH terms
- Adult, Aged, Aged, 80 and over, Diagnosis, Differential, Female, Gastritis, Atrophic, Humans, Male, Middle Aged, Sensitivity and Specificity, Biomarkers, Tumor, Zollinger-Ellison Syndrome, Case-Control Studies, Neuroendocrine Tumors, Enterochromaffin-like Cells, Chromogranin A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
